JP2017534638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534638A5 JP2017534638A5 JP2017524049A JP2017524049A JP2017534638A5 JP 2017534638 A5 JP2017534638 A5 JP 2017534638A5 JP 2017524049 A JP2017524049 A JP 2017524049A JP 2017524049 A JP2017524049 A JP 2017524049A JP 2017534638 A5 JP2017534638 A5 JP 2017534638A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- pharmaceutical composition
- mammal
- bcva
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 37
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 23
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 23
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 23
- 230000009266 disease activity Effects 0.000 claims description 20
- 208000031513 cyst Diseases 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 230000004304 visual acuity Effects 0.000 claims description 14
- 210000001525 retina Anatomy 0.000 claims description 12
- 206010011732 Cyst Diseases 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076770P | 2014-11-07 | 2014-11-07 | |
| US62/076,770 | 2014-11-07 | ||
| US201462088061P | 2014-12-05 | 2014-12-05 | |
| US62/088,061 | 2014-12-05 | ||
| PCT/US2015/059575 WO2016073918A1 (en) | 2014-11-07 | 2015-11-06 | Methods for treating ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138531A Division JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534638A JP2017534638A (ja) | 2017-11-24 |
| JP2017534638A5 true JP2017534638A5 (enExample) | 2018-12-06 |
| JP6753848B2 JP6753848B2 (ja) | 2020-09-09 |
Family
ID=54697654
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523878A Active JP6667519B2 (ja) | 2014-11-07 | 2015-11-06 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2017524049A Active JP6753848B2 (ja) | 2014-11-07 | 2015-11-06 | 眼疾患を処置する方法 |
| JP2020000823A Active JP7080263B2 (ja) | 2014-11-07 | 2020-01-07 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2020138531A Withdrawn JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
| JP2022119423A Pending JP2022141923A (ja) | 2014-11-07 | 2022-07-27 | 眼疾患を処置する方法 |
| JP2024170733A Pending JP2025004075A (ja) | 2014-11-07 | 2024-09-30 | 眼疾患を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523878A Active JP6667519B2 (ja) | 2014-11-07 | 2015-11-06 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000823A Active JP7080263B2 (ja) | 2014-11-07 | 2020-01-07 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2020138531A Withdrawn JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
| JP2022119423A Pending JP2022141923A (ja) | 2014-11-07 | 2022-07-27 | 眼疾患を処置する方法 |
| JP2024170733A Pending JP2025004075A (ja) | 2014-11-07 | 2024-09-30 | 眼疾患を処置する方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10689438B2 (enExample) |
| EP (3) | EP4684797A2 (enExample) |
| JP (6) | JP6667519B2 (enExample) |
| KR (4) | KR20240161204A (enExample) |
| CN (4) | CN107635580A (enExample) |
| AU (6) | AU2015342818B2 (enExample) |
| BR (2) | BR112017008660A2 (enExample) |
| CA (1) | CA2966646A1 (enExample) |
| CL (2) | CL2017001115A1 (enExample) |
| CO (1) | CO2017004596A2 (enExample) |
| EA (1) | EA201790989A1 (enExample) |
| EC (1) | ECSP17034829A (enExample) |
| ES (1) | ES3051145T3 (enExample) |
| GT (1) | GT201700096A (enExample) |
| IL (5) | IL251642B (enExample) |
| MX (3) | MX383399B (enExample) |
| MY (2) | MY183807A (enExample) |
| NZ (1) | NZ730821A (enExample) |
| PE (1) | PE20170780A1 (enExample) |
| PH (3) | PH12021550147A1 (enExample) |
| RU (1) | RU2722643C2 (enExample) |
| SG (3) | SG10201913565RA (enExample) |
| TN (1) | TN2017000128A1 (enExample) |
| TW (4) | TWI705827B (enExample) |
| WO (2) | WO2016073915A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY150400A (en) | 2006-04-07 | 2014-01-15 | Aerpio Therapeutics Inc | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| KR101834797B1 (ko) | 2008-06-25 | 2018-03-07 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| KR20210065201A (ko) | 2008-06-25 | 2021-06-03 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| MX349901B (es) | 2011-01-13 | 2017-08-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CN107206080B (zh) | 2015-01-28 | 2022-07-08 | 辉瑞公司 | 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂 |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| CA3006432A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| JP6644956B2 (ja) * | 2016-09-07 | 2020-02-12 | サクシン ライフサイエンシス ピーヴィーティー エルティディーＳａｋｓｉｎ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｐｖｔ Ｌｔｄ | Ｖｅｇｆに対する合成の抗体およびそれらの使用 |
| CA3038894A1 (en) | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| TWI780082B (zh) | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| CN109562166B (zh) * | 2017-04-28 | 2021-04-02 | 苏州思坦维生物技术股份有限公司 | 一种眼用药物组合物及其用途 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| WO2019020777A1 (en) * | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| SG11202002490UA (en) | 2017-10-06 | 2020-04-29 | Prothena Biosciences Ltd | Methods of detecting transthyretin |
| WO2019071205A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETIN ANTIBODY |
| EP3717512A4 (en) * | 2017-11-29 | 2021-08-25 | Prothena Biosciences Limited | LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETIN |
| MX2020005166A (es) | 2017-11-30 | 2020-09-03 | Regeneron Pharma | Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos. |
| IL310376B1 (en) | 2018-01-26 | 2025-10-01 | Univ California | Methods and compositions for treating angiogenic disorders using anti-VEGF factors |
| CN119909169A (zh) * | 2018-02-06 | 2025-05-02 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| KR20200131839A (ko) * | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| MX2020009935A (es) * | 2018-03-23 | 2021-01-08 | Abbvie Deutschland | Formulaciones acuosas y estables de anticuerpos anti-tau. |
| WO2019200006A2 (en) * | 2018-04-10 | 2019-10-17 | Askgene Pharma Inc. | Novel angiopoietin 2, vegf dual antagonists |
| AU2019265005B2 (en) | 2018-05-10 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| CA3100317A1 (en) | 2018-05-17 | 2019-11-21 | Astellas Pharma Inc. | Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand |
| EP3856245A4 (en) * | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| WO2020075746A1 (ja) * | 2018-10-10 | 2020-04-16 | アステラス製薬株式会社 | 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物 |
| BR112021007946A2 (pt) * | 2018-10-29 | 2021-08-03 | F. Hoffmann-La Roche Ag | formulação de anticorpo |
| MX2021005382A (es) | 2018-11-07 | 2021-11-12 | Applied Molecular Transport Inc | Vehiculos derivados de cholix para suministro oral de carga util heterologa. |
| AR117707A1 (es) * | 2018-12-18 | 2021-08-25 | Novartis Ag | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
| CN113474360B (zh) | 2019-02-18 | 2025-01-07 | 伊莱利利公司 | 治疗性抗体制剂 |
| TWI862583B (zh) | 2019-04-26 | 2024-11-21 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
| JP7564824B2 (ja) | 2019-04-29 | 2024-10-09 | アイポイント ファーマシューティカルズ， インコーポレイテッド | シュレム管を標的とするＴｉｅ－２活性化物質 |
| KR20220066056A (ko) | 2019-08-16 | 2022-05-23 | 어플라이드 몰레큘라 트랜스포트 인크. | 조성물, 제형, 및 인터루킨 제조 및 정제 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| CN111217834B (zh) * | 2020-02-21 | 2021-10-26 | 维眸生物科技（上海）有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
| US20230192832A1 (en) * | 2020-03-04 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Pharmaceutical formulation comprising bevacizumab |
| CN113698478B (zh) * | 2020-05-21 | 2025-11-18 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| KR20220001106A (ko) | 2020-06-29 | 2022-01-05 | (주)메디톡스 | 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체 |
| CR20230009A (es) | 2020-07-16 | 2023-01-25 | Novartis Ag | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas |
| EP4185318B1 (en) * | 2021-05-17 | 2025-09-03 | Regeneron Pharmaceuticals, Inc. | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| CN113940997B (zh) * | 2021-12-21 | 2022-04-08 | 迈威(上海)生物科技股份有限公司 | 一种双特异性抗体的稳定制剂 |
| JP2025529465A (ja) * | 2022-09-16 | 2025-09-04 | チールー ファーマシューティカル カンパニー、リミテッド | 安定な高濃度自己緩衝医薬組成物 |
| WO2025231345A1 (en) * | 2024-05-03 | 2025-11-06 | Therini Bio, Inc. | Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| NZ596663A (en) | 2004-10-21 | 2013-07-26 | Genentech Inc | Use of vegf antagonists in intraocular neovascular disease treatment |
| WO2007011873A2 (en) * | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| SI2364691T1 (sl) * | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| PE20090329A1 (es) | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| KR20210065201A (ko) | 2008-06-25 | 2021-06-03 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| ES2793008T3 (es) * | 2008-06-25 | 2020-11-12 | Novartis Ag | Anticuerpos estables y solubles que inhiben VEGF |
| KR101834797B1 (ko) | 2008-06-25 | 2018-03-07 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| JP5988580B2 (ja) | 2008-06-30 | 2016-09-07 | エスバテック − ア ノバルティス カンパニー エルエルシー | 機能性ポリペプチド |
| CN102770158B (zh) | 2009-12-21 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| MX349901B (es) * | 2011-01-13 | 2017-08-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. |
| CN107090038A (zh) | 2011-06-30 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 抗c‑met抗体配制剂 |
| TWI577696B (zh) * | 2011-10-20 | 2017-04-11 | Ｅｓｂａ科技 諾華有限責任公司 | 穩定的多重抗原結合抗體 |
| NZ741873A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| NZ751452A (en) | 2013-03-13 | 2020-04-24 | Genentech Inc | Antibody formulations |
| WO2015086830A1 (en) * | 2013-12-13 | 2015-06-18 | Delenex Therapeutics Ag | Skin penetrating polypeptides |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| BR112016029864A2 (pt) * | 2014-06-17 | 2017-08-22 | Clearside Biomedical Inc | métodos e dispositivos para tratamento de desordens oculares posteriores. |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| KR20200131839A (ko) | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| AR117707A1 (es) | 2018-12-18 | 2021-08-25 | Novartis Ag | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
-
2015
- 2015-10-26 TW TW104135104A patent/TWI705827B/zh active
- 2015-10-26 TW TW104135105A patent/TWI738632B/zh active
- 2015-10-26 TW TW110133255A patent/TWI806150B/zh active
- 2015-10-26 TW TW109132401A patent/TWI761959B/zh active
- 2015-11-06 AU AU2015342818A patent/AU2015342818B2/en active Active
- 2015-11-06 MY MYPI2017701217A patent/MY183807A/en unknown
- 2015-11-06 TN TN2017000128A patent/TN2017000128A1/en unknown
- 2015-11-06 EP EP25187400.4A patent/EP4684797A2/en active Pending
- 2015-11-06 JP JP2017523878A patent/JP6667519B2/ja active Active
- 2015-11-06 WO PCT/US2015/059571 patent/WO2016073915A1/en not_active Ceased
- 2015-11-06 MX MX2017005875A patent/MX383399B/es unknown
- 2015-11-06 CN CN201580060416.5A patent/CN107635580A/zh active Pending
- 2015-11-06 EA EA201790989A patent/EA201790989A1/ru unknown
- 2015-11-06 MY MYPI2020002268A patent/MY193913A/en unknown
- 2015-11-06 SG SG10201913565RA patent/SG10201913565RA/en unknown
- 2015-11-06 AU AU2015342815A patent/AU2015342815B2/en active Active
- 2015-11-06 KR KR1020247035792A patent/KR20240161204A/ko not_active Ceased
- 2015-11-06 SG SG11201702954XA patent/SG11201702954XA/en unknown
- 2015-11-06 US US14/934,666 patent/US10689438B2/en active Active
- 2015-11-06 EP EP15807721.4A patent/EP3215123A1/en active Pending
- 2015-11-06 CN CN201580060665.4A patent/CN106999581A/zh active Pending
- 2015-11-06 EP EP15798609.2A patent/EP3215122B1/en active Active
- 2015-11-06 ES ES15798609T patent/ES3051145T3/es active Active
- 2015-11-06 PE PE2017000812A patent/PE20170780A1/es unknown
- 2015-11-06 NZ NZ73082115A patent/NZ730821A/en unknown
- 2015-11-06 US US14/934,731 patent/US10035850B2/en active Active
- 2015-11-06 CN CN202511153148.3A patent/CN120938921A/zh active Pending
- 2015-11-06 RU RU2017119647A patent/RU2722643C2/ru active
- 2015-11-06 CA CA2966646A patent/CA2966646A1/en active Pending
- 2015-11-06 PH PH1/2021/550147A patent/PH12021550147A1/en unknown
- 2015-11-06 KR KR1020177012256A patent/KR20170082526A/ko not_active Ceased
- 2015-11-06 SG SG11201702909QA patent/SG11201702909QA/en unknown
- 2015-11-06 CN CN202111376360.8A patent/CN114081951A/zh active Pending
- 2015-11-06 WO PCT/US2015/059575 patent/WO2016073918A1/en not_active Ceased
- 2015-11-06 KR KR1020237014727A patent/KR102724014B1/ko active Active
- 2015-11-06 KR KR1020177014978A patent/KR102588846B1/ko active Active
- 2015-11-06 BR BR112017008660A patent/BR112017008660A2/pt not_active Application Discontinuation
- 2015-11-06 JP JP2017524049A patent/JP6753848B2/ja active Active
- 2015-11-06 BR BR112017008093-1A patent/BR112017008093A2/pt not_active Application Discontinuation
- 2015-11-06 MX MX2017005874A patent/MX383808B/es unknown
-
2017
- 2017-04-06 IL IL251642A patent/IL251642B/en active IP Right Grant
- 2017-04-12 IL IL251696A patent/IL251696A0/en active IP Right Grant
- 2017-05-04 MX MX2021006768A patent/MX2021006768A/es unknown
- 2017-05-05 CL CL2017001115A patent/CL2017001115A1/es unknown
- 2017-05-05 GT GT201700096A patent/GT201700096A/es unknown
- 2017-05-05 PH PH12017500844A patent/PH12017500844B1/en unknown
- 2017-05-05 PH PH12017500843A patent/PH12017500843A1/en unknown
- 2017-05-05 CL CL2017001117A patent/CL2017001117A1/es unknown
- 2017-05-05 CO CONC2017/0004596A patent/CO2017004596A2/es unknown
- 2017-06-05 EC ECIEPI201734829A patent/ECSP17034829A/es unknown
-
2018
- 2018-06-26 US US16/018,244 patent/US11098110B2/en active Active
- 2018-12-04 AU AU2018274882A patent/AU2018274882B2/en active Active
- 2018-12-11 AU AU2018278870A patent/AU2018278870B2/en active Active
-
2019
- 2019-03-20 IL IL265497A patent/IL265497B/en active IP Right Grant
-
2020
- 2020-01-07 JP JP2020000823A patent/JP7080263B2/ja active Active
- 2020-05-11 US US16/871,765 patent/US12049495B2/en active Active
- 2020-08-19 JP JP2020138531A patent/JP2020193212A/ja not_active Withdrawn
- 2020-08-21 AU AU2020220210A patent/AU2020220210B2/en active Active
- 2020-10-05 AU AU2020244614A patent/AU2020244614B2/en active Active
-
2021
- 2021-01-11 IL IL280087A patent/IL280087B/en unknown
- 2021-05-30 IL IL283561A patent/IL283561B/en unknown
- 2021-07-16 US US17/378,618 patent/US12371481B2/en active Active
-
2022
- 2022-07-27 JP JP2022119423A patent/JP2022141923A/ja active Pending
-
2024
- 2024-09-30 JP JP2024170733A patent/JP2025004075A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534638A5 (enExample) | ||
| RU2017119647A (ru) | Способ лечения болезней глаз | |
| JP2017501129A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| EP4279135A3 (en) | Use of a vegf antagonist to treat diabetic retinopathy | |
| JP2019511222A5 (enExample) | ||
| JP2021509668A (ja) | 免疫抑制なしにｉｌ−６媒介性炎症を処置する方法 | |
| JP2015522576A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| JP2010509369A5 (enExample) | ||
| JP2017501130A5 (enExample) | ||
| WO2020097511A3 (en) | Messenger rna therapy for treatment of ocular diseases | |
| Lee et al. | Effect of a broad-specificity chemokine-binding protein on brain leukocyte infiltration and infarct development | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2014240408A5 (enExample) | ||
| JP2015528454A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2016521712A5 (enExample) | ||
| JP2017523776A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2016520615A5 (enExample) | ||
| JP2017535285A5 (enExample) | ||
| JP2018534259A5 (enExample) | ||
| JP2019528285A5 (enExample) |